NCT05244057View on ClinicalTrials.gov

A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

Hepalatide

6.3mg, s.c., qd for 48 weeks

DRUG

Placebo of Hepalatide

s.c., qd for 48 weeks

DRUG

Tenofovir Alafenamide Tablets

25mg, p.o., qd for 48 weeks

DRUG

Pegylated Interferon alfa 2a

90ug, s.c., qw for 48 weeks

Trial Locations (1)

200050

Shanghai Tong Ren Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Tong Ren Hospital

OTHER

collaborator

Shanghai East Hospital

OTHER

lead

Shanghai HEP Pharmaceutical Co., Ltd.

INDUSTRY